Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT Consortium: Diabetologia

RobertW. Koivula; Alison Heggie; Anna Barnett; Henna Cederberg; Tue Haldor Hansen; AnitraD. Koopman; Martin Ridderstråle; Femke Rutters; Henrik Vestergaard; Ramneek Gupta; Sanna Herrgård; MartijnW. Heymans; MandyH. Perry; Simone Rauh; Maritta Siloaho; HarrietJ.A. Teare; Barbara Thorand; Jimmy Bell; Søren Brunak; Gary Frost; Bernd Jablonka; Andrea Mari; TimJ. McDonald; JacquelineM. Dekker; Torben Hansen; Andrew Hattersley; Markku Laakso; Oluf Pedersen; Veikko Koivisto; Hartmut Ruetten; Mark Walker; Ewan Pearson; PaulW. Franks

doi:10.1007/s00125-014-3216-x

Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT Consortium: Diabetologia

RobertW. Koivula, Alison Heggie, Anna Barnett, Henna Cederberg, Tue Haldor Hansen, AnitraD. Koopman, Martin Ridderstråle, Femke Rutters, Henrik Vestergaard, Ramneek Gupta, Sanna Herrgård, MartijnW. Heymans, MandyH. Perry, Simone Rauh, Maritta Siloaho, HarrietJ.A. Teare, Barbara Thorand, Jimmy Bell, Søren Brunak, Gary FrostBernd Jablonka, Andrea Mari, TimJ. McDonald, JacquelineM. Dekker, Torben Hansen, Andrew Hattersley, Markku Laakso, Oluf Pedersen, Veikko Koivisto, Hartmut Ruetten, Mark Walker, Ewan Pearson, PaulW. Franks

32 Citations (Scopus)

Abstract

Aims/hypothesis: The DIRECT (Diabetes Research on Patient Stratification) Study is part of a European Union Framework 7 Innovative Medicines Initiative project, a joint undertaking between four industry and 21 academic partners throughout Europe. The Consortium aims to discover and validate biomarkers that: (1) predict the rate of glycaemic deterioration before and after type 2 diabetes onset; (2) predict the response to diabetes therapies; and (3) help stratify type 2 diabetes into clearly definable disease subclasses that can be treated more effectively than without stratification. This paper describes two new prospective cohort studies conducted as part of DIRECT. Methods: Prediabetic participants (target sample size 2,200-2,700) and patients with newly diagnosed type 2 diabetes (target sample size ~1,000) are undergoing detailed metabolic phenotyping at baseline and 18 months and 36 months later. Abdominal, pancreatic and liver fat is assessed using MRI. Insulin secretion and action are assessed using frequently sampled OGTTs in non-diabetic participants, and frequently sampled mixed-meal tolerance tests in patients with type 2 diabetes. Biosamples include venous blood, faeces, urine and nail clippings, which, among other biochemical analyses, will be characterised at genetic, transcriptomic, metabolomic, proteomic and metagenomic levels. Lifestyle is assessed using high-resolution triaxial accelerometry, 24 h diet record, and food habit questionnaires. Conclusions/interpretation: DIRECT will yield an unprecedented array of biomaterials and data. This resource, available through managed access to scientists within and outside the Consortium, will facilitate the development of new treatments and therapeutic strategies for the prevention and management of type 2 diabetes.

Original language	English
Journal	Diabetologia
Volume	57
Issue number	6
Pages (from-to)	1-11
Number of pages	11
ISSN	0012-186X
DOIs	https://doi.org/10.1007/s00125-014-3216-x
Publication status	Published - Jun 2014

Keywords

Epigenetic
Gene–environment interaction
Genome
Glycaemic control
Lifestyle
Microbiome
Prediabetes
Proteome
Transcriptome
Type 2 diabetes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00125-014-3216-x

Cite this

Koivula, R., Heggie, A., Barnett, A., Cederberg, H., Hansen, T. H., Koopman, A., Ridderstråle, M., Rutters, F., Vestergaard, H., Gupta, R., Herrgård, S., Heymans, M., Perry, M., Rauh, S., Siloaho, M., Teare, H. A., Thorand, B., Bell, J., Brunak, S., ... Franks, P. (2014). Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT Consortium: Diabetologia. Diabetologia, 57(6), 1-11. https://doi.org/10.1007/s00125-014-3216-x

Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT Consortium: Diabetologia. / Koivula, RobertW.; Heggie, Alison; Barnett, Anna et al.
In: Diabetologia, Vol. 57, No. 6, 06.2014, p. 1-11.

Research output: Contribution to journal › Journal article › Research › peer-review

Koivula, R, Heggie, A, Barnett, A, Cederberg, H, Hansen, TH, Koopman, A, Ridderstråle, M, Rutters, F, Vestergaard, H, Gupta, R, Herrgård, S, Heymans, M, Perry, M, Rauh, S, Siloaho, M, Teare, HA, Thorand, B, Bell, J, Brunak, S, Frost, G, Jablonka, B, Mari, A, McDonald, T, Dekker, J, Hansen, T, Hattersley, A, Laakso, M, Pedersen, O, Koivisto, V, Ruetten, H, Walker, M, Pearson, E & Franks, P 2014, 'Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT Consortium: Diabetologia', Diabetologia, vol. 57, no. 6, pp. 1-11. https://doi.org/10.1007/s00125-014-3216-x

@article{7023333c24014adaa2c3521e70d659a6,

title = "Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT Consortium: Diabetologia",

abstract = "Aims/hypothesis: The DIRECT (Diabetes Research on Patient Stratification) Study is part of a European Union Framework 7 Innovative Medicines Initiative project, a joint undertaking between four industry and 21 academic partners throughout Europe. The Consortium aims to discover and validate biomarkers that: (1) predict the rate of glycaemic deterioration before and after type 2 diabetes onset; (2) predict the response to diabetes therapies; and (3) help stratify type 2 diabetes into clearly definable disease subclasses that can be treated more effectively than without stratification. This paper describes two new prospective cohort studies conducted as part of DIRECT. Methods: Prediabetic participants (target sample size 2,200-2,700) and patients with newly diagnosed type 2 diabetes (target sample size ~1,000) are undergoing detailed metabolic phenotyping at baseline and 18 months and 36 months later. Abdominal, pancreatic and liver fat is assessed using MRI. Insulin secretion and action are assessed using frequently sampled OGTTs in non-diabetic participants, and frequently sampled mixed-meal tolerance tests in patients with type 2 diabetes. Biosamples include venous blood, faeces, urine and nail clippings, which, among other biochemical analyses, will be characterised at genetic, transcriptomic, metabolomic, proteomic and metagenomic levels. Lifestyle is assessed using high-resolution triaxial accelerometry, 24 h diet record, and food habit questionnaires. Conclusions/interpretation: DIRECT will yield an unprecedented array of biomaterials and data. This resource, available through managed access to scientists within and outside the Consortium, will facilitate the development of new treatments and therapeutic strategies for the prevention and management of type 2 diabetes.",

keywords = "Epigenetic, Gene–environment interaction, Genome, Glycaemic control, Lifestyle, Microbiome, Prediabetes, Proteome, Transcriptome, Type 2 diabetes",

author = "RobertW. Koivula and Alison Heggie and Anna Barnett and Henna Cederberg and Hansen, {Tue Haldor} and AnitraD. Koopman and Martin Ridderstr{\aa}le and Femke Rutters and Henrik Vestergaard and Ramneek Gupta and Sanna Herrg{\aa}rd and MartijnW. Heymans and MandyH. Perry and Simone Rauh and Maritta Siloaho and HarrietJ.A. Teare and Barbara Thorand and Jimmy Bell and S{\o}ren Brunak and Gary Frost and Bernd Jablonka and Andrea Mari and TimJ. McDonald and JacquelineM. Dekker and Torben Hansen and Andrew Hattersley and Markku Laakso and Oluf Pedersen and Veikko Koivisto and Hartmut Ruetten and Mark Walker and Ewan Pearson and PaulW. Franks",

year = "2014",

month = jun,

doi = "10.1007/s00125-014-3216-x",

language = "English",

volume = "57",

pages = "1--11",

journal = "Diabetologia",

issn = "0012-186X",

publisher = "Springer",

number = "6",

}

TY - JOUR

T1 - Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT Consortium

T2 - Diabetologia

AU - Koivula, RobertW.

AU - Heggie, Alison

AU - Barnett, Anna

AU - Cederberg, Henna

AU - Hansen, Tue Haldor

AU - Koopman, AnitraD.

AU - Ridderstråle, Martin

AU - Rutters, Femke

AU - Vestergaard, Henrik

AU - Gupta, Ramneek

AU - Herrgård, Sanna

AU - Heymans, MartijnW.

AU - Perry, MandyH.

AU - Rauh, Simone

AU - Siloaho, Maritta

AU - Teare, HarrietJ.A.

AU - Thorand, Barbara

AU - Bell, Jimmy

AU - Brunak, Søren

AU - Frost, Gary

AU - Jablonka, Bernd

AU - Mari, Andrea

AU - McDonald, TimJ.

AU - Dekker, JacquelineM.

AU - Hansen, Torben

AU - Hattersley, Andrew

AU - Laakso, Markku

AU - Pedersen, Oluf

AU - Koivisto, Veikko

AU - Ruetten, Hartmut

AU - Walker, Mark

AU - Pearson, Ewan

AU - Franks, PaulW.

PY - 2014/6

Y1 - 2014/6

N2 - Aims/hypothesis: The DIRECT (Diabetes Research on Patient Stratification) Study is part of a European Union Framework 7 Innovative Medicines Initiative project, a joint undertaking between four industry and 21 academic partners throughout Europe. The Consortium aims to discover and validate biomarkers that: (1) predict the rate of glycaemic deterioration before and after type 2 diabetes onset; (2) predict the response to diabetes therapies; and (3) help stratify type 2 diabetes into clearly definable disease subclasses that can be treated more effectively than without stratification. This paper describes two new prospective cohort studies conducted as part of DIRECT. Methods: Prediabetic participants (target sample size 2,200-2,700) and patients with newly diagnosed type 2 diabetes (target sample size ~1,000) are undergoing detailed metabolic phenotyping at baseline and 18 months and 36 months later. Abdominal, pancreatic and liver fat is assessed using MRI. Insulin secretion and action are assessed using frequently sampled OGTTs in non-diabetic participants, and frequently sampled mixed-meal tolerance tests in patients with type 2 diabetes. Biosamples include venous blood, faeces, urine and nail clippings, which, among other biochemical analyses, will be characterised at genetic, transcriptomic, metabolomic, proteomic and metagenomic levels. Lifestyle is assessed using high-resolution triaxial accelerometry, 24 h diet record, and food habit questionnaires. Conclusions/interpretation: DIRECT will yield an unprecedented array of biomaterials and data. This resource, available through managed access to scientists within and outside the Consortium, will facilitate the development of new treatments and therapeutic strategies for the prevention and management of type 2 diabetes.

AB - Aims/hypothesis: The DIRECT (Diabetes Research on Patient Stratification) Study is part of a European Union Framework 7 Innovative Medicines Initiative project, a joint undertaking between four industry and 21 academic partners throughout Europe. The Consortium aims to discover and validate biomarkers that: (1) predict the rate of glycaemic deterioration before and after type 2 diabetes onset; (2) predict the response to diabetes therapies; and (3) help stratify type 2 diabetes into clearly definable disease subclasses that can be treated more effectively than without stratification. This paper describes two new prospective cohort studies conducted as part of DIRECT. Methods: Prediabetic participants (target sample size 2,200-2,700) and patients with newly diagnosed type 2 diabetes (target sample size ~1,000) are undergoing detailed metabolic phenotyping at baseline and 18 months and 36 months later. Abdominal, pancreatic and liver fat is assessed using MRI. Insulin secretion and action are assessed using frequently sampled OGTTs in non-diabetic participants, and frequently sampled mixed-meal tolerance tests in patients with type 2 diabetes. Biosamples include venous blood, faeces, urine and nail clippings, which, among other biochemical analyses, will be characterised at genetic, transcriptomic, metabolomic, proteomic and metagenomic levels. Lifestyle is assessed using high-resolution triaxial accelerometry, 24 h diet record, and food habit questionnaires. Conclusions/interpretation: DIRECT will yield an unprecedented array of biomaterials and data. This resource, available through managed access to scientists within and outside the Consortium, will facilitate the development of new treatments and therapeutic strategies for the prevention and management of type 2 diabetes.

KW - Epigenetic

KW - Gene–environment interaction

KW - Genome

KW - Glycaemic control

KW - Lifestyle

KW - Microbiome

KW - Prediabetes

KW - Proteome

KW - Transcriptome

KW - Type 2 diabetes

U2 - 10.1007/s00125-014-3216-x

DO - 10.1007/s00125-014-3216-x

M3 - Journal article

C2 - 24695864

SN - 0012-186X

VL - 57

SP - 1

EP - 11

JO - Diabetologia

JF - Diabetologia

IS - 6

ER -

Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT Consortium: Diabetologia

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this